Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Teva Pharmaceutical Industries : EU regulators charge Teva over pay-for-delay drug deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2017 | 01:36pm CEST
A building belonging to Teva Pharmaceutical Industries, the world's biggest generic drugmaker and Israel's largest company, is seen in Jerusalem

BRUSSELS (Reuters) - EU antitrust regulators charged Israeli drugmaker Teva (>> Teva Pharmaceutical Industries Limited) on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug, putting it at risk of a fine.

BRUSSELS (Reuters) - EU antitrust regulators charged Israeli drugmaker Teva (>> Teva Pharmaceutical Industries Limited) <TEVA.N> on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug, putting it at risk of a fine.

The crackdown by the European Commission follows fines against scores of companies including Denmark's Lundbeck, U.S. giant Johnson & Johnson and France's Servier in recent years over similar deals.

The EU competition enforcer's 2009 inquiry into the sector showed that so-called pay-for-delay deals cost European consumers billions of euros.

Teva, the world's biggest generic drugmaker, reached the deal with Cephalon as part of a settlement to end a lawsuit over alleged infringement of Cephalon's patents on the blockbuster drug. This involved cash payments from Cephalon, which Teva later acquired in 2011.

The Commission said the deal may have pushed up prices of the drug, modafinil.

"The patent settlement agreement between Cephalon and Teva may have caused substantial harm to EU patients and health service budgets," the EU competition enforcer said in a statement.

Teva said it strongly disagreed with the Commission's analysis on such deals.

"We do not believe that Cephalon and Teva entered into any anti-competitive behavior," the company said.

Teva, which can ask for a closed-door hearing to defend its case, can be fined up to 10 percent of its global turnover if found guilty of breaching EU antitrust rules. The company made $21.9 billion of revenue in 2016.

It was fined 15.6 million euros ($17.9 million) in 2014 for an illegal deal with Servier.

The Commission in May sent a warning shot to the sector by opening an investigation into alleged excessive pricing by South Africa's Aspen Pharmacare (>> Aspen Pharmacare Holdings Limited) for five cancer medicines.

(Reporting by Foo Yun Chee; Additional reporting by Ari Rabinovitch in Jerusalem; Editing by Philip Blenkinsop and Mark Potter)

By Foo Yun Chee

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
04/26TEVA PHARMACEUTICAL INDUSTRIES : Three Teva directors to leave board
AQ
04/26TEVA PHARMACEUTICAL INDUSTRIES : and the Procter & Gamble Company Have Agreed to..
AQ
04/26TEVA PHARMACEUTICAL INDUSTRIES : to Report First Quarter 2018 Financial Results ..
AQ
04/26TEVA PHARMACEUTICAL INDUSTRIES : to reduce size of board after June shareholders..
RE
04/24TEVA PHARMACEUTICAL INDUSTRIES : Histadrut slams Teva management over Ashdod pla..
AQ
04/24PROCTER & GAMBLE : Teva and the Procter & Gamble Company Have Agreed to Terminat..
AQ
04/24PROCTER & GAMBLE : P&G Announces Third Quarter Earnings
AQ
04/23TEVA PHARMACEUTICAL INDUSTRIES : to Report First Quarter 2018 Financial Results ..
BU
04/23PROCTER & GAMBLE : P&G Announces Third Quarter Earnings; Net Sales +4%; Organic ..
AQ
04/23P&G Acquires the Consumer Health Business of Merck KGaA, Darmstadt, Germany
AQ
More news
News from SeekingAlpha
04/26The European Central Bank Updates, And The EU Monitors Imports (Wall Street B.. 
04/26WALL STREET BREAKFAST : Mario Draghi Takes The Stage 
04/26Three Teva directors to leave board 
04/26Opioid prescriptions dropped 12% in 2017 
04/24BY THE NUMBERS : Healthcare Stocks With Big Cash Distributions 
Financials ($)
Sales 2018 19 600 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0,94x
Capi. / Sales 2019 0,94x
Capitalization 18 421 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 18,5 $
Spread / Average Target 8,1%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-5.76%18 421
JOHNSON & JOHNSON-9.68%338 522
PFIZER2.32%220 455
NOVARTIS-8.69%202 567
ROCHE HOLDING LTD.-11.66%193 904
MERCK AND COMPANY5.97%161 967